Ranger Investment Management L.P. Acquires New Shares in iRadimed Corporation $IRMD

Ranger Investment Management L.P. purchased a new stake in shares of iRadimed Corporation (NASDAQ:IRMD) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 98,346 shares of the medical equipment provider’s stock, valued at approximately $9,398,000. Ranger Investment Management L.P. owned about 0.77% of iRadimed at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in IRMD. BlackRock Inc. bought a new position in shares of iRadimed during the 2nd quarter valued at $92,485,000. Vanguard Group Inc. boosted its holdings in iRadimed by 1.0% in the third quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock worth $40,313,000 after purchasing an additional 5,475 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in iRadimed by 410.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after purchasing an additional 205,783 shares in the last quarter. Dimensional Fund Advisors LP increased its position in iRadimed by 4.2% during the first quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock worth $21,768,000 after buying an additional 9,017 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in iRadimed by 37.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock worth $19,964,000 after buying an additional 55,426 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

Insider Activity

In related news, CEO Roger E. Susi sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the sale, the chief executive officer directly owned 2,162,500 shares of the company’s stock, valued at $195,922,500. The trade was a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 34.60% of the company’s stock.

Wall Street Analyst Weigh In

IRMD has been the subject of a number of analyst reports. Weiss Ratings cut shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, August 3rd. Wall Street Zen lowered shares of iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $120.00.

iRadimed Price Performance

Shares of IRMD stock opened at $87.85 on Monday. iRadimed Corporation has a one year low of $67.84 and a one year high of $107.90. The stock has a fifty day moving average price of $93.39 and a 200 day moving average price of $94.46. The stock has a market cap of $1.12 billion, a P/E ratio of 49.08 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02. The company had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Equities research analysts anticipate that iRadimed Corporation will post 1.98 EPS for the current year.

iRadimed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Investors of record on Friday, August 14th will be issued a $0.20 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is currently 44.69%.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.